COOPERATION AGREEMENTCooperation Agreement • February 22nd, 2023 • Rubric Capital Management LP • Pharmaceutical preparations • Delaware
Contract Type FiledFebruary 22nd, 2023 Company Industry JurisdictionThis Cooperation Agreement, dated as of February 21, 2023 (this “Agreement”), is made by and among Heron Therapeutics, Inc., a Delaware corporation (the “Company”), Rubric Capital Management LP, a Delaware limited partnership (and collectively with the other persons and entities listed on Schedule A hereto, “Rubric”), and Velan Capital Investment Management LP, a Delaware limited partnership (and collectively with the other persons and entities listed on Schedule B hereto, “Velan” and, together with Rubric, the “Investor Group,” and, for clarity and as applicable, including each member thereof acting individually). The Company and each member of the Investor Group are collectively herein referred to as the “Parties” and individually as a “Party.” Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in Section 22 below.
COOPERATION AGREEMENTCooperation Agreement • October 28th, 2022 • Rubric Capital Management LP • Pharmaceutical preparations
Contract Type FiledOctober 28th, 2022 Company IndustryThis cooperation agreement, dated October 28, 2022 (this “Agreement”), is by and between Mereo BioPharma Group plc, a company incorporated under the laws of England and Wales with registered number 09481161 and having its registered office at 4th Floor, One, Cavendish Place, London, England, W1G 0QF (the “Company”) and Rubric Capital Management L.P., a limited partnership formed under the laws of the state of Delaware with its principal office at 155 East 44th St, Suite 1630, New York, NY 10017 (collectively with its Affiliates and Associates, “Rubric”). The Company and Rubric are each herein referred to as a “party” and, collectively, the “parties.” In consideration of, and reliance upon, the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which is acknowledged, the parties agree as follows:
GROUP AGREEMENTGroup Agreement • February 6th, 2023 • Rubric Capital Management LP • Pharmaceutical preparations
Contract Type FiledFebruary 6th, 2023 Company IndustryTHIS AGREEMENT, dated as of January 30, 2023 (the “Effective Date”), is by and between (i) Velan Capital Master Fund LP, Velan Capital Holdings LLC, Velan Capital Investment Management LP, Velan Capital Management LLC, Adam Morgan and Balaji Venkataraman (collectively, “Velan”) and (ii) Rubric Capital Management LP and in his capacity as managing member of Rubric Capital Management GP LLC, David Rosen (collectively, “Rubric”) (each of the foregoing, a “Party” and, collectively, the “Parties” or the “Group”).
JOINT FILING AGREEMENTJoint Filing Agreement • February 22nd, 2023 • Rubric Capital Management LP • Pharmaceutical preparations
Contract Type FiledFebruary 22nd, 2023 Company IndustryIn accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.01 per share, of Heron Therapeutics, Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
JOINT FILING AND SOLICITATION AGREEMENTJoint Filing and Solicitation Agreement • January 23rd, 2024 • Rubric Capital Management LP • Services-prepackaged software
Contract Type FiledJanuary 23rd, 2024 Company IndustryWHEREAS, certain of the undersigned are stockholders, direct or beneficial, of Xperi Inc., a Delaware corporation (the “Company”); and
JOINT FILING AGREEMENTJoint Filing Agreement • May 31st, 2024 • Rubric Capital Management LP • Services-prepackaged software
Contract Type FiledMay 31st, 2024 Company IndustryIn accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the common stock, par value $0.001 per share, of Xperi Inc., a Delaware corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.